Рак поджелудочной железы: достижения иммунотерапии и лечение током. Новости онкологии

Врач онколог Федоринов Денис Сергеевич Источники: Chen Z, He Y, Ding C, Chen J, Gu Y, Xiao M, Li Q. Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study. Onco Targets Ther. 2023 Nov 9;16:923-935. doi: PMID: 37965584; PMCID: PMC10642393. Cheng D, Hu J, Wu X, Wang B, Chen R, Zhao W, Fang C, Ji M. PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study. Front Oncol. 2023 Oct 27;13:1281545. doi: PMID: 37965469; PMCID: PMC10641475. Nicolle R, Bachet JB, Harlé A, Iovanna J, Hammel P, Rebours V, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lopez A, Biagi J, François E, Artru P, Lambert A, Renouf DJ, Monard L, Mauduit M, Dusetti N, Conroy T, Cros J. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial. J Clin Oncol. 2023 Nov 14:JCO2202668. doi: Epub ahead of print. PMID: 37963313. Liu C, Fan L, Wu Q, Shi Y, Sun X. Prognostic significance of PD-L1 expression in pancreatic cancer: evidence from an updated meta-analysis. Pol J Pathol. 2023;74(3):151-160. doi: PMID: 37955534. Jo Y, Lee E, Oh G, Gi Y, Yoon M. Synergistic effect of TTF and 5-FU combination treatment on pancreatic cancer cells. Am J Cancer Res. 2023 Oct 15;13(10):4734-4741. PMID: 37970358; PMCID: PMC10636678.